Search results for the GEO ID: GSE10946
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM277438
GPL570
cumulus_nonPCOS_Lean_rep1 luteinized human cumulus cells, cultured 48h, nonPCOS, Lean, rep1 Gender: Female, Age: 28, BMI: 17, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277439
GPL570
cumulus_nonPCOS_Lean_rep2 luteinized human cumulus cells, cultured 48h, nonPCOS, Lean, rep2 Gender: Female, Age: 27, BMI: 21, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277440
GPL570
cumulus_nonPCOS_Lean_rep3 luteinized human cumulus cells, cultured 48h, nonPCOS, Lean, rep3 Gender: Female, Age: 30, BMI: 24, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277441
GPL570
cumulus_nonPCOS_Lean_rep4 luteinized human cumulus cells, cultured 48h, nonPCOS, Lean, rep4 Gender: Female, Age: 25, BMI: 16, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277442
GPL570
cumulus_nonPCOS_Lean_rep5 luteinized human cumulus cells, cultured 48h, nonPCOS, Lean, rep5 Gender: Female, Age: 31, BMI: 21, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277443
GPL570
cumulus_nonPCOS_Lean_rep6 luteinized human cumulus cells, cultured 48h, nonPCOS, Lean, rep6 Gender: Female, Age: 29, BMI: 22, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277444
GPL570
cumulus_nonPCOS_Obese_rep1 luteinized human cumulus cells, cultured 48h, nonPCOS, Obese, rep1 Gender: Female, Age: 35, BMI: 27, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277445
GPL570
cumulus_nonPCOS_Obese_rep2 luteinized human cumulus cells, cultured 48h, nonPCOS, Obese, rep2 Gender: Female, Age: 33, BMI: 33, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277446
GPL570
cumulus_nonPCOS_Obese_rep3 luteinized human cumulus cells, cultured 48h, nonPCOS, Obese, rep3 Gender: Female, Age: 28, BMI: 34, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277447
GPL570
cumulus_nonPCOS_Obese_rep4 luteinized human cumulus cells, cultured 48h, nonPCOS, Obese, rep4 Gender: Female, Age: 32, BMI: 30, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277448
GPL570
cumulus_nonPCOS_Obese_rep5 luteinized human cumulus cells, cultured 48h, nonPCOS, Obese, rep5 Gender: Female, Age: 28, BMI: 30, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277449
GPL570
cumulus_PCOS_Lean_rep1 luteinized human cumulus cells, cultured 48h, PCOS, Lean, rep1 Gender: Female, Age: 27, BMI: 19, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277450
GPL570
cumulus_PCOS_Lean_rep2 luteinized human cumulus cells, cultured 48h, PCOS, Lean, rep2 Gender: Female, Age: 35, BMI: 22, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277451
GPL570
cumulus_PCOS_Lean_rep3 luteinized human cumulus cells, cultured 48h, PCOS, Lean, rep3 Gender: Female, Age: 25, BMI: 23, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277452
GPL570
cumulus_PCOS_Lean_rep4 luteinized human cumulus cells, cultured 48h, PCOS, Lean, rep4 Gender: Female, Age: 32, BMI: 25, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277453
GPL570
cumulus_PCOS_Lean_rep5 luteinized human cumulus cells, cultured 48h, PCOS, Lean, rep5 Gender: Female, Age: 28, BMI: 17.1, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277454
GPL570
cumulus_PCOS_Obese_rep1 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep1 Gender: Female, Age: 25, BMI: 31, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277455
GPL570
cumulus_PCOS_Obese_rep2 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep2 Gender: Female, Age: 358, BMI: 30, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277456
GPL570
cumulus_PCOS_Obese_rep3 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep3 Gender: Female, Age: 37, BMI: 31, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277457
GPL570
cumulus_PCOS_Obese_rep4 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep4 Gender: Female, Age: 31, BMI: 37, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277458
GPL570
cumulus_PCOS_Obese_rep5 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep5 Gender: Female, Age: 27, BMI: 29, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277459
GPL570
cumulus_PCOS_Obese_rep6 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep6 Gender: Female, Age: 25, BMI: 32, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
GSM277460
GPL570
cumulus_PCOS_Obese_rep7 luteinized human cumulus cells, cultured 48h, PCOS, Obese, rep7 Gender: Female, Age: 37, BMI: 31, Tissue: luteinized cumulus cells All the participants included in the study were women undergoing In-Vitro Fertilization with intracytoplasmatic sperm injection (IVF-ICSI) at the IVF unit. The IVF-ICSI cycles included in the study were conducted according to the long mid luteal GnRH agonist (Diphereline 3.75 mg PharmaBiotech, France) protocol. Controlled ovarian hyperstimulation was conducted with either recombinant follicular stimulating hormone (rFSH- Follitropin Alfa, Serono, UK) or human menopausal gonadotropin (hMG - Menotropin, Ferring, Germany). Following oocyte retrieval, cumulus cells were stripped from the oocyte, in preparation for the ICSI process, with a micropipette.
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes